Search

Your search keyword '"Guan, Jinghong"' showing total 39 results
Start Over Author "Guan, Jinghong"
39 results on '"Guan, Jinghong"'

2. Aggravated Primary Lymphedema of Contralateral Upper Limb After the Radical Mastectomy: A Case Report

Author

LIU Ying, PAN Weiren, GUAN Jinghong, ZHAO Wowa, and LONG Xiao

Subjects
primary lymphedema, breast cancer-related lymphedema, manual lymphatic drainage, Medicine
Abstract

Lymphedema is a hot issue that has attracted wide attention in the field of rehabilitation medicine in recent years. The complex decongestive therapy of lymphedema including manual lymphatic drainage(MLD) as the key technology is developing rapidly all over the country.We report a rare case of aggravated primary lymphedema in the contralateral limb and trunk after radical mastectomy. The patient achieved remission through MLD treatment. By reviewing the diagnosis and treatment of this case, we can deepen the understanding of the complexity of the pathogenesis of lymphedema and provide reference for individualized diagnosis and treatment of lymphedema.

Published
2022
Full Text
View/download PDF

8. Abstract P1-12-03: Antidiarrheal prophylaxis with loperamide for patients with lymph node-negative (N0) or micrometastatic (N1mi), HER2-positive breast cancer who received adjuvant pyrotinib plus nab-paclitaxel: a randomized sub-study of PHAEDRA

Author

Wang, Changjun, primary, Lin, Yan, additional, Zhou, Yidong, additional, Mao, Feng, additional, Guan, Jinghong, additional, Shen, Songjie, additional, Wang, Xuejing, additional, Zhang, Xiaohui, additional, Zhang, Yanna, additional, Pan, Bo, additional, Zhong, Ying, additional, Peng, Li, additional, Li, Yan, additional, Huang, Xin, additional, Xu, Ying, additional, and Sun, Qiang, additional

Published
2023
Full Text
View/download PDF

12. Abstract OT1-12-03: Phase II study of pyrotinib plus nanoparticle albumin-bound (nab)-paclitaxel as adjuvant therapy for lymph node-negative (N0) or micrometastatic (N1mi), HER2-positive early breast cancer (PHAEDRA)

Author

Wang, Changjun, primary, Zhou, Yidong, additional, Lin, Yan, additional, Mao, Feng, additional, Guan, Jinghong, additional, Zhang, Xiaohui, additional, Shen, Songjie, additional, Wang, Xuejing, additional, Zhang, Yanna, additional, Pan, Bo, additional, Zhong, Ying, additional, Peng, Li, additional, Cao, Xi, additional, Yao, Ru, additional, Zhou, Xingtong, additional, Xu, Chi, additional, Xu, Ying, additional, and Sun, Qiang, additional

Published
2022
Full Text
View/download PDF

20. Phosphatidylinositol-3,4,5-Trisphosphate Dependent Rac Exchange Factor 1 (PREX1) is a Novel Predictor of Prognosis for Breast Cancer Patients: A Retrospective Case Series

Author

Zhong, Ying, primary, Zhang, Jing, additional, Zhou, Yidong, additional, Mao, Feng, additional, Lin, Yan, additional, Xu, Yali, additional, Guan, Jinghong, additional, Shen, Songjie, additional, Pan, Bo, additional, Wang, Changjun, additional, Peng, Li, additional, Huang, Xin, additional, Li, Yan, additional, Cao, Xi, additional, and Sun, Qiang, additional

Published
2019
Full Text
View/download PDF

21. GnRHa for Ovarian Protection and the Association between AMH and Ovarian Function during Adjuvant Chemotherapy for Breast Cancer

Author

Zhong, Ying, primary, Lin, Yan, additional, Cheng, Xinqi, additional, Huang, Xin, additional, Zhou, Yidong, additional, Mao, Feng, additional, Wang, Yajing, additional, Guan, Jinghong, additional, Shen, Songjie, additional, Xu, Yali, additional, Peng, Li, additional, li, Yan, additional, Cao, Xi, additional, and Sun, Qiang, additional

Published
2019
Full Text
View/download PDF

30. NOTCH1 is a poor prognostic factor for breast cancer and is associated with breast cancer stem cells

Author

Zhong,Ying, Shen,Songjie, Zhou,Yidong, Mao,Feng, Lin,Yan, Guan,Jinghong, Xu,Yali, Zhang,Shu, Liu,Xu, Sun,Qiang, Zhong,Ying, Shen,Songjie, Zhou,Yidong, Mao,Feng, Lin,Yan, Guan,Jinghong, Xu,Yali, Zhang,Shu, Liu,Xu, and Sun,Qiang

Abstract

Ying Zhong,1 Songjie Shen,1 Yidong Zhou,1 Feng Mao,1 Yan Lin,1 Jinghong Guan,1 Yali Xu,1 Shu Zhang,2 Xu Liu,3 Qiang Sun1 1Department of Breast Disease, 2Department of Dermatology, Peking Union Medical College Hospital, 3Centralab Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, People’s Republic of China Abstract: Recently, the human gene NOTCH1 has been found to be implicated in cancer cell metastasis and the maintenance of cancer stem cells. However, for breast cancer in particular, an association between NOTCH1 levels and metastasis has not been determined. In this study, we investigated the expression status and correlation of NOTCH1 with clinically important factors related to metastasis and the cancer stem cell marker ALDH1. NOTCH1 and ALDH1 levels in 115 tumor tissues from primary lesions were determined by immunohistochemical staining. Most tissues were stained positive for both NOTCH1 and ALDH1, and NOTCH1 positivity was significantly associated with ALDH1 levels. NOTCH1 levels were significantly associated with TNM stage, metastasis, and triple-negative breast cancer. Moreover, both univariate and multivariate regression analyses revealed that basal-like features and NOTCH1 positivity were associated with disease-free survival as independent predictors. These analyses indicated that breast cancer patients testing positive for NOTCH1 had shorter disease-free survival. Our findings suggest that NOTCH1 may be involved in metastasis and is closely correlated with breast cancer stem cells. Keywords: breast cancer, NOTCH1, metastasis, ALDH1, cancer stem cell

Published
2016

31. TTK is a favorable prognostic biomarker for triple-negative breast cancer survival

Author

Xu, Qianqian, primary, Xu, Yali, additional, Pan, Bo, additional, Wu, Liangcai, additional, Ren, Xinyu, additional, Zhou, Yidong, additional, Mao, Feng, additional, Lin, Yan, additional, Guan, Jinghong, additional, Shen, Songjie, additional, Zhang, Xiaohui, additional, Wang, Changjun, additional, Zhong, Ying, additional, Zhou, Liangrui, additional, Liang, Zhiyong, additional, Zhao, Haitao, additional, and Sun, Qiang, additional

Published
2016
Full Text
View/download PDF

37. Ultrasound-Assisted Thoracic Paravertebral Block Reduces Intraoperative Opioid Requirement and Improves Analgesia after Breast Cancer Surgery: A Randomized, Controlled, Single-Center Trial.

Author

Pei, Lijian, Zhou, Yidong, Tan, Gang, Mao, Feng, Yang, Dongsheng, Guan, Jinghong, Lin, Yan, Wang, Xuejing, Zhang, Yanna, Zhang, Xiaohui, Shen, Songjie, Xu, Zhonghuang, Sun, Qiang, Huang, Yuguang, and null, null

Subjects
BREAST cancer treatment, BREAST cancer surgery, ULTRASONIC imaging, DRUG therapy, OPIOIDS, ANALGESIA, RANDOMIZED controlled trials
Abstract

Objectives: The contribution of ultrasound-assisted thoracic paravertebral block to postoperative analgesia remains unclear. We compared the effect of a combination of ultrasound assisted-thoracic paravertebral block and propofol general anesthesia with opioid and sevoflurane general anesthesia on volatile anesthetic, propofol and opioid consumption, and postoperative pain in patients having breast cancer surgery. Methods: Patients undergoing breast cancer surgery were randomly assigned to ultrasound-assisted paravertebral block with propofol general anesthesia (PPA group, n = 121) or fentanyl with sevoflurane general anesthesia (GA group, n = 126). Volatile anesthetic, propofol and opioid consumption, and postoperative pain intensity were compared between the groups using noninferiority and superiority tests. Results: Patients in the PPA group required less sevoflurane than those in the GA group (median [interquartile range] of 0 [0, 0] vs. 0.4 [0.3, 0.6] minimum alveolar concentration [MAC]-hours), less intraoperative fentanyl requirements (100 [50, 100] vs. 250 [200, 300]μg,), less intense postoperative pain (median visual analog scale score 2 [1, 3.5] vs. 3 [2, 4.5]), but more propofol (median 529 [424, 672] vs. 100 [100, 130] mg). Noninferiority was detected for all four outcomes; one-tailed superiority tests for each outcome were highly significant at P<0.001 in the expected directions. Conclusions: The combination of propofol anesthesia with ultrasound-assisted paravertebral block reduces intraoperative volatile anesthetic and opioid requirements, and results in less post operative pain in patients undergoing breast cancer surgery. Trial Registration: ClinicalTrial.gov [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

38. Diagnosis and treatment of gastric stromal tumors: report of 70 cases

Author

Wu, Bin, Qiu, Huizhong, Guan, Jinghong, Lin, Guole, and Zhao, Yupei

Abstract

Abstract: Objective: To investigate the diagnosis and treatment of gastric stromal tumors (GSTs). Methods: The clinical data from 70 cases with GSTs were analyzed retrospectively. Results: Wedge resections were performed on 32 patients and major gastrectomies on 38 patients. The median tumor size was 5.4cm in diameter and 2 out of 70 cases (2.9% ) indicated positive lymph node metastasis. Immunohistochemical staining showed 66 out of 70 (94.3%) were positive for CD117, 53 (75.7%) positive for CD34, 24 positive for SMA and 8 positive for Desmin and S100. Ten out of 70 cases recurred or metastasized. The 5-year survival rate in this series was 71.3%. The 5-year survival rate of benign and malignant GSTs were 92.3% and 61.8% (P<0.05) respectively. The 5-year survival rate for tumors of size <5 cm and ≥5 cm were 95.0% and 48.4% (P< 0.05), respectively. Conclusion: The primary treatment for gastric stromal tumors is surgery. Tumor size and mitotic counts were observed to be important prognostic indicators.

Published
1996
Full Text
View/download PDF

39. [Trastuzumab administered concurrently with anthracycline-containing adjuvant regimen for breast cancer].

Author

Shen S, Xu Y, Sun Q, Wang C, Zhou Y, Mao F, Guan J, Lin Y, Wang X, and Han S

Subjects
Adult, Breast Neoplasms pathology, Breast Neoplasms surgery, Carcinoma, Ductal, Breast pathology, Carcinoma, Ductal, Breast surgery, Chemotherapy, Adjuvant, Disease-Free Survival, Female, Follow-Up Studies, Humans, Liver Neoplasms secondary, Lymphatic Metastasis, Middle Aged, Neoplasm Recurrence, Local, Prospective Studies, Stroke Volume, Trastuzumab, Anthracyclines administration & dosage, Antibodies, Monoclonal, Humanized administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms drug therapy, Carcinoma, Ductal, Breast drug therapy
Abstract

Objective: To investigate the safety and efficacy of trastuzumab administered concurrently with anthracycline-containing adjuvant regimen for breast cancer., Methods: It is a prospective, randomized and controlled trial. Participants were randomized to receive trastuzumab administered concurrently or sequentially with anthracycline-containing adjuvant regimen. The primary endpoint was cardiac safety. The second endpoints were disease-free survival (DFS) and overall survival (OS)., Results: One hundred and nine breast cancer patients were enrolled and randomized in this trial. Fifty-five participants received trastuzumab administered concurrently with anthracycline-containing adjuvant regimen and 54 patients received trastuzumab administered sequentially with anthracycline. The primary cardiac event was asymptomatic decrease in the left ventricular ejection fraction (LVEF). There was no significant difference between concurrent and sequential groups in cardiac event rates (9.1% vs13.0%, P = 0.556), neither of LVEF values at basline or at 3, 6, 9 and 12 months during trastuzumab treatment (P > 0.05). Four patients (7.3%) in the concurrent group suffered local recurrences or distant metastases, and 6 participants (11.1%) in the sequential group had distant metastases. There was no significant difference between the two groups in DFS (P = 0.724). There was no death in both groups., Conclusions: Trastuzumab administered concurrently with anthracycline is a safe adjuvant regimen for breast cancer and does not increase cardiac events. Further research is needed to determine the efficacy of this treatment regimen.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results